BiotechTube
Bio-Diagnostics

Bio-Diagnostics

London, United Kingdom· Est.
biodiagnostics.co.uk
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Bio-Diagnostics is a privately held, established UK biotech firm founded in 1979 (not 1995 as per initial data), operating as a market leader in allergy testing and treatments. The company has diversified into four main divisions: Immunology, Immunohistochemistry, Dermatology, and Allergy, supported by its proprietary QuickCard/BioCard rapid diagnostic platform. It generates revenue through product sales, distribution, and a comprehensive suite of B2B services including contract manufacturing, R&D, and laboratory testing. The company is revenue-generating, with a strong service-oriented business model and a focus on the UK and international markets.

AllergyAutoimmune DiseasesInfectious Disease

Technology Platform

Proprietary QuickCard™/BioCard™ platform: a credit card-sized, adaptable rapid diagnostic testing device designed for point-of-care use. It features structural innovations and adaptable biochemistries for accurate results, manufactured in-house from UK-sourced materials.

Opportunities

The growing demand for point-of-care and home testing, especially post-pandemic, presents a major opportunity for its BioCard™ platform.
Additionally, its offer of a fully regulated UK facility for manufacturing, testing, and certification provides a critical service to international companies navigating post-Brexit regulations, creating a significant new B2B revenue stream.

Risk Factors

Key risks include dependence on exclusive distribution agreements, concentration in the UK market, ongoing regulatory compliance costs for IVDs, and competition in the rapid diagnostic platform space from larger, well-funded companies.
Supply chain disruptions, despite a predominantly UK base, also pose a potential threat.

Competitive Landscape

Bio-Diagnostics competes in niche segments against larger global IVD companies (like Thermo Fisher, Danaher) in distribution and antibodies, and against other specialty allergy and autoimmune diagnostic firms. Its competitive advantages are its deep UK market expertise, integrated service model, control over its proprietary platform's manufacturing, and its post-Brexit regulatory positioning as a UK-based partner.

More companies in United Kingdom →